The takeaway
Viking Therapeutics Inc shows a pronounced seasonal pattern over 10 years of data — strongest in December (+16.4%) and softest in March (−5.1%).
Right now
In July, the stock has risen 50% of years, averaging +2.1% — essentially in line with the S&P 500.
The full picture
Viking Therapeutics Inc's most dependable month has been December, higher in 6 of 10 years; March has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in February (+23.1 pts); it has trailed the market most in March (−6.1 pts).
“vs S&P” is Viking Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Viking Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 60% of the time versus 60% across the last 10 years — the pattern is weakening.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
December looks the standout, up in 6 of 10 Decembers — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +16.4% average sits well above the +7.2% a typical year delivers, the work of a few big Decembers. That reliability comes with real swings, mind — even December ranges by 43.3% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +15.4 points above the index.
Only November comes anywhere near it for reliability. The weaker half of the year is plainer: March has been the soft spot — the weakest of 3 months that average a loss (−5.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, June, and November. Its roughest month on record was a −37.5% January in 2016 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, December's last five years slipping below its longer-run record.
Hold it loosely, then: the December tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (December), its worst (March), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (December, +16.4%) has run well ahead of its worst (March, −5.1%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +16.4% and closing higher in 6 of 10 years since 2016.
It's the weakest, averaging −5.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade